Oz Ibrahim Ilker, Serifoglu Ismail, Bilici Muammer, Altinbas Namik Kemal, Oz Evrim Bozay, Akduman Ece Isin
1 Department of Radiology, School of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
2 Department of Radiology, Bagcilar Training and Research Hospital, Istanbul, Turkey.
Vasc Endovascular Surg. 2016 Nov;50(8):534-540. doi: 10.1177/1538574416676019. Epub 2016 Nov 11.
To consider the clinical outcomes and restenosis rates of drug-eluting balloons (DEBs) and percutaneous transluminal angioplasty (PTA) in diabetic patients with infrapopliteal (IP) arterial disease.
This retrospective, single-center study included 51 patients (37 males; mean age: 63.43 ± 9.81 years) with diabetes mellitus having IP arterial disease, from October 2012 to September 2014. Twenty-two patients were treated with PTA, and 29 patients were treated with DEBs. After intervention, the patients were evaluated in the first week and every 3 months, clinically and radiologically. Univariate and multivariate analyses were used to evaluate the clinical outcomes of diabetic patients with IP arterial disease who were treated with either DEBs or PTA.
There were no statistically significant differences between the groups in terms of age and gender, risk factors, characteristics of lesions, or the diameters or length of the balloons ( P > .05). Primary patency was higher in the DEB group than in the PTA group (97.8% vs 81.1%, P = .020) in the first 3 months. However, there was no statistically significant difference at 1-year follow-up (68.2% vs 48.5%, P = .131). At the 12-month follow-up, there was no difference in clinical improvement between the groups ( P = .193).
The findings of this study reveal that DEB is a safe alternative treatment method for IP arterial disease in diabetic patients.
探讨药物洗脱球囊（DEB）和经皮腔内血管成形术（PTA）治疗糖尿病患者腘下（IP）动脉疾病的临床疗效和再狭窄率。
本回顾性单中心研究纳入了2012年10月至2014年9月期间51例患有IP动脉疾病的糖尿病患者（37例男性；平均年龄：63.43±9.81岁）。22例患者接受PTA治疗，29例患者接受DEB治疗。干预后，在第一周及之后每3个月对患者进行临床和影像学评估。采用单因素和多因素分析评估接受DEB或PTA治疗的糖尿病IP动脉疾病患者的临床疗效。
两组在年龄、性别、危险因素、病变特征或球囊直径及长度方面无统计学显著差异（P>.05）。在最初3个月，DEB组的原发性通畅率高于PTA组（97.8%对81.1%，P=.020）。然而，在1年随访时无统计学显著差异（68.2%对48.5%，P=.131）。在12个月随访时，两组间临床改善情况无差异（P=.193）。
本研究结果表明，DEB是糖尿病患者IP动脉疾病的一种安全替代治疗方法。
